tetano
Editor, Senior Moderator
Front Immunol
. 2022 Oct 31;13:960094.
doi: 10.3389/fimmu.2022.960094. eCollection 2022.
SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
Zheng Liu[SUP] 1 [/SUP], Chenglu Yang[SUP] 1 [/SUP], Haokun Zhang[SUP] 1 [/SUP], Guojie Cao[SUP] 1 [/SUP], Senzhen Wang[SUP] 1 [/SUP], Siwen Yin[SUP] 1 [/SUP], Yanming Wang[SUP] 1 [/SUP]
Affiliations
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy and calls for the development of safe treatments and effective vaccines. The receptor-binding domain in the spike protein (S[SUP]RBD[/SUP]) of SARS-CoV-2 is responsible for its binding to angiotensin-converting enzyme 2 (ACE2) receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that dimeric S[SUP]RBD[/SUP]-Fc and tetrameric 2xS[SUP]RBD[/SUP]-Fc fusion proteins bind ACE2 with different affinity and block SARS-CoV-2 pseudoviral infection. Immunization of mice with S[SUP]RBD[/SUP]-Fc fusion proteins elicited high titer of RBD-specific antibodies with robust neutralizing activity against pseudoviral infections. As such, our study indicates that the polymeric S[SUP]RBD[/SUP]-Fc fusion protein can serve as a treatment agent as well as a vaccine for fighting COVID-19.
Keywords: 2xS-RBD-mFc; SARS-CoV-2; Vaccine; hACE2; viral infection.
. 2022 Oct 31;13:960094.
doi: 10.3389/fimmu.2022.960094. eCollection 2022.
SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response
Zheng Liu[SUP] 1 [/SUP], Chenglu Yang[SUP] 1 [/SUP], Haokun Zhang[SUP] 1 [/SUP], Guojie Cao[SUP] 1 [/SUP], Senzhen Wang[SUP] 1 [/SUP], Siwen Yin[SUP] 1 [/SUP], Yanming Wang[SUP] 1 [/SUP]
Affiliations
- PMID: 36389744
- PMCID: PMC9659643
- DOI: 10.3389/fimmu.2022.960094
Abstract
The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed serious threats to global health and economy and calls for the development of safe treatments and effective vaccines. The receptor-binding domain in the spike protein (S[SUP]RBD[/SUP]) of SARS-CoV-2 is responsible for its binding to angiotensin-converting enzyme 2 (ACE2) receptor. It contains multiple dominant neutralizing epitopes and serves as an important antigen for the development of COVID-19 vaccines. Here, we showed that dimeric S[SUP]RBD[/SUP]-Fc and tetrameric 2xS[SUP]RBD[/SUP]-Fc fusion proteins bind ACE2 with different affinity and block SARS-CoV-2 pseudoviral infection. Immunization of mice with S[SUP]RBD[/SUP]-Fc fusion proteins elicited high titer of RBD-specific antibodies with robust neutralizing activity against pseudoviral infections. As such, our study indicates that the polymeric S[SUP]RBD[/SUP]-Fc fusion protein can serve as a treatment agent as well as a vaccine for fighting COVID-19.
Keywords: 2xS-RBD-mFc; SARS-CoV-2; Vaccine; hACE2; viral infection.